tiprankstipranks
Company Announcements

Genscript Biotech Schedules Board Meeting to Approve 2024 Results

Story Highlights
  • Genscript Biotech operates in the biotechnology industry with a focus on biotech products.
  • The company will hold a board meeting to approve 2024 results and consider a final dividend.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Genscript Biotech Schedules Board Meeting to Approve 2024 Results

The latest announcement is out from Genscript Biotech ( (HK:1548) ).

Genscript Biotech Corporation has announced a board meeting scheduled for March 11, 2025, to discuss and approve the company’s final results for the year ending December 31, 2024. The meeting will also consider the potential payment of a final dividend, highlighting the company’s ongoing financial management and potential shareholder returns.

More about Genscript Biotech

Genscript Biotech Corporation is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It focuses on providing various biotech products and services, with a market presence indicated by its listing on the Hong Kong Stock Exchange under the stock code 1548.

YTD Price Performance: 49.61%

Average Trading Volume: 4,728

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $3.73B

For a thorough assessment of 1548 stock, go to TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1